Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CASTLE BIOSCIENCES INCCSTL · Entity 359 | Chief Financial Officer | August 14, 2026 | August 18, 2026 |
| EXAGEN INC.XGN · Entity 935 | Director | June 09, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CASTLE BIOSCIENCES INC
Report date August 14, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,177 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Sale · Disposed 24,908 · Balance 35,177 F1: This transaction was executed in multiple trades at prices ranging from $29.71 to $29.97, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $29.71 to $29.97, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
EXAGEN INC.
Report date June 09, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.31 · Expires 2036-06-08 | Direct | 112,500 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 37,500 · Balance 112,500 F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 18, 2026 20:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 24,908 | $29.77 | $741,511.16 |
DisclosureSEC source: 0001628280-26-057644 · wk-form4_1787083838.xml · nonDerivative · entry 1 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,177 F1 · price: This transaction was executed in multiple trades at prices ranging from $29.71 to $29.97, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 09, 2026 Filed Jun 22, 2026 17:00 UTC | EXAGEN INC. XGN · Entity 935 | GrantStock Option(right to buy) · Derivative | 37,500 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001782815-26-000007 · wk-form4_1782147613.xml · derivative · entry 1 Stokes Frank · CIK 0001782815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 37,500 shares Expires 2036-06-08 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:13 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 6,001 | $27.98 | $167,907.98 |
DisclosureSEC source: 0001628280-26-016019 · wk-form4_1773087231.xml · nonDerivative · entry 1 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,085 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Frank Stokes on November 13, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.51 to $28.41, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 22:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 3,800 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001628280-26-015334 · wk-form4_1772748515.xml · derivative · entry 10 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,912 Underlying: Common Stock · 3,800 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The shares subject to the option are fully vested. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 22:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 11,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015334 · wk-form4_1772748515.xml · derivative · entry 9 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,878 Underlying: Common Stock · 11,960 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F9 · derivative.exercise_date: On March 4, 2025, the Reporting Person was granted 47,838 RSUs which vest in four equal installments beginning on March 4, 2026. F9 · derivative.expiration_date: On March 4, 2025, the Reporting Person was granted 47,838 RSUs which vest in four equal installments beginning on March 4, 2026. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 22:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 12,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015334 · wk-form4_1772748515.xml · derivative · entry 8 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,372 Underlying: Common Stock · 12,186 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F8 · derivative.exercise_date: On March 4, 2024, the Reporting Person was granted 48,744 RSUs which vest in four equal installments beginning on March 4, 2025. F8 · derivative.expiration_date: On March 4, 2024, the Reporting Person was granted 48,744 RSUs which vest in four equal installments beginning on March 4, 2025. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 22:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 3,800 | $3.38 | $12,844.00 |
DisclosureSEC source: 0001628280-26-015334 · wk-form4_1772748515.xml · nonDerivative · entry 6 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 22:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Tax withholdingCommon Stock | 10,732 | $28.17 | $302,320.44 |
DisclosureSEC source: 0001628280-26-015334 · wk-form4_1772748515.xml · nonDerivative · entry 5 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,286 Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 22:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 24,146 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-015334 · wk-form4_1772748515.xml · nonDerivative · entry 4 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 22:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantRestricted Stock Units · Derivative | 48,367 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015334 · wk-form4_1772748515.xml · derivative · entry 7 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,367 Underlying: Common Stock · 48,367 shares Expires not disclosed F6 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: The RSU's vest in four equal annual installments beginning on March 03, 2027. F7 · derivative.expiration_date: The RSU's vest in four equal annual installments beginning on March 03, 2027. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 22:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Tax withholdingCommon Stock | 3,611 | $27.57 | $99,555.27 |
DisclosureSEC source: 0001628280-26-015334 · wk-form4_1772748515.xml · nonDerivative · entry 3 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,872 F5 · shares: Reflects the withholding of shares of the Issuer's common stock to satisfy tax withholding obligations in connection with the delivery of vested performance stock units reported on January 12, 2026. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 22:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,700 | $27.81 | $47,277.00 |
DisclosureSEC source: 0001628280-26-015334 · wk-form4_1772748515.xml · nonDerivative · entry 2 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,483 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Frank Stokes on November 13, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $27.72 to $27.97, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 22:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 5,300 | $27.32 | $144,796.00 |
DisclosureSEC source: 0001628280-26-015334 · wk-form4_1772748515.xml · nonDerivative · entry 1 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,183 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Frank Stokes on November 13, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $26.70 to $27.67, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: Includes 1,033 shares acquired on February 27, 2026, under the Issuer's employee stock purchase plan. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:30 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantPerformance-Based Stock Unit · Derivative | 8,124 | $0.00 | $0.00 |
DisclosureSEC source: 0001782815-26-000002 · form4-01142026_040101.xml · derivative · entry 2 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,124 Underlying: Common Stock · 8,124 shares Expires not disclosed F2 · derivative.exercise_price: Each PSU represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the 2024 PSUs which will vest subject to the achievement of certain milestones. F2 · derivative.exercise_date: Each PSU represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the 2024 PSUs which will vest subject to the achievement of certain milestones. F2 · derivative.expiration_date: Each PSU represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the 2024 PSUs which will vest subject to the achievement of certain milestones. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:30 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantCommon Stock | 8,124 | $0.00 | $0.00 |
DisclosureSEC source: 0001782815-26-000002 · form4-01142026_040101.xml · nonDerivative · entry 1 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,450 F1 · shares: Represents 50% of the Performance-Based Stock Units ("PSUs") granted on March 4, 2024 ("2024 PSUs") that vested based on the satisfaction of certain performance criteria as certified by the board of directors of the Issuer on January 12, 2026. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 21:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,496 | $37.45 | $168,375.20 |
DisclosureSEC source: 0001628280-25-057013 · wk-form4_1765832936.xml · nonDerivative · entry 1 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,326 Read SEC document |
| December 10, 2025 Filed Dec 11, 2025 23:46 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 6,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-056627 · wk-form4_1765496775.xml · derivative · entry 6 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,170 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On December 10, 2021, the Reporting Person was granted 24,679 RSUs which vest in four equal installments beginning on December 10, 2022. F3 · derivative.expiration_date: On December 10, 2021, the Reporting Person was granted 24,679 RSUs which vest in four equal installments beginning on December 10, 2022. Read SEC document |
| December 10, 2025 Filed Dec 11, 2025 23:46 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Tax withholdingCommon Stock | 2,758 | $38.02 | $104,859.16 |
DisclosureSEC source: 0001628280-25-056627 · wk-form4_1765496775.xml · nonDerivative · entry 4 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,822 Read SEC document |
| December 10, 2025 Filed Dec 11, 2025 23:46 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 6,170 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-056627 · wk-form4_1765496775.xml · nonDerivative · entry 3 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 23:46 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 14,616 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-056627 · wk-form4_1765496775.xml · derivative · entry 5 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,617 Underlying: Common Stock · 14,616 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On December 9, 2022, the Reporting Person was granted 58,467 RSUs which vest in four equal installments beginning on December 9, 2023. F2 · derivative.expiration_date: On December 9, 2022, the Reporting Person was granted 58,467 RSUs which vest in four equal installments beginning on December 9, 2023. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 23:46 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Tax withholdingCommon Stock | 6,534 | $38.25 | $249,925.50 |
DisclosureSEC source: 0001628280-25-056627 · wk-form4_1765496775.xml · nonDerivative · entry 2 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,410 Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 23:46 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 14,616 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-056627 · wk-form4_1765496775.xml · nonDerivative · entry 1 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 21:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 5,388 | $35.08 | $189,011.04 |
DisclosureSEC source: 0001628280-25-052021 · wk-form4_1763068128.xml · nonDerivative · entry 1 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,328 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Frank Stokes on August 12, 2025 F2 · price: This transaction was executed in multiple trades at prices ranging from $34.44 to $35.37, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 20:31 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionPerformance-Based Stock Unit · Derivative | 9,744 | $0.00 | $0.00 |
DisclosureSEC source: 0001782815-25-000003 · wk-form4_1755030694.xml · derivative · entry 3 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,744 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Performance-Based Stock Unit ("PSU") represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the PSUs granted on December 23, 2022, which were all subject to time-based vesting and vested in full on the one-year anniversary of August 9, 2024. F1 · derivative.exercise_date: Each Performance-Based Stock Unit ("PSU") represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the PSUs granted on December 23, 2022, which were all subject to time-based vesting and vested in full on the one-year anniversary of August 9, 2024. F1 · derivative.expiration_date: Each Performance-Based Stock Unit ("PSU") represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the PSUs granted on December 23, 2022, which were all subject to time-based vesting and vested in full on the one-year anniversary of August 9, 2024. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 20:31 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Tax withholdingCommon Stock | 4,356 | $19.36 | $84,332.16 |
DisclosureSEC source: 0001782815-25-000003 · wk-form4_1755030694.xml · nonDerivative · entry 2 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,716 Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 20:31 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 9,744 | $0.00 | $0.00 |
DisclosureSEC source: 0001782815-25-000003 · wk-form4_1755030694.xml · nonDerivative · entry 1 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 22:49 UTC | EXAGEN INC. XGN · Entity 935 | GrantStock Option(right to buy) · Derivative | 9,000 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0001274737-25-000048 · wk-form4_1749768534.xml · derivative · entry 1 Stokes Frank · CIK 0001782815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2035-06-09 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 12,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-25-000034 · wk-form4_1741295420.xml · derivative · entry 4 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,558 Underlying: Common Stock · 12,186 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On March 4, 2024, the Reporting Person was granted 48,744 RSUs which vest in four equal installments beginning on March 4, 2025. F4 · derivative.expiration_date: On March 4, 2024, the Reporting Person was granted 48,744 RSUs which vest in four equal installments beginning on March 4, 2025. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantRestricted Stock Units · Derivative | 47,838 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-25-000034 · wk-form4_1741295420.xml · derivative · entry 3 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,838 Underlying: Common Stock · 47,838 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSU's vest in four equal annual installments beginning on March 04, 2026. F3 · derivative.expiration_date: The RSU's vest in four equal annual installments beginning on March 04, 2026. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Tax withholdingCommon Stock | 5,448 | $22.23 | $121,109.04 |
DisclosureSEC source: 0001447362-25-000034 · wk-form4_1741295420.xml · nonDerivative · entry 2 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,328 Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:10 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 12,186 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001447362-25-000034 · wk-form4_1741295420.xml · nonDerivative · entry 1 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 1,271 shares acquired on February 28, 2025, under the Issuer's employee stock purchase plan. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 21:23 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 8,046 | $26.70 | $214,828.20 |
DisclosureSEC source: 0001447362-25-000019 · wk-form4_1740432180.xml · nonDerivative · entry 1 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,319 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Frank Stokes on November 18, 2024 F2 · price: This transaction was executed in multiple trades at prices ranging from $26.47 to $27.10, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 10, 2024 Filed Dec 11, 2024 21:51 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 6,169 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-24-000196 · wk-form4_1733953906.xml · derivative · entry 9 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,170 Underlying: Common Stock · 6,169 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On December 10, 2021, the Reporting Person was granted 24,679 RSUs which vest in four equal installments beginning on December 10, 2022. F4 · derivative.expiration_date: On December 10, 2021, the Reporting Person was granted 24,679 RSUs which vest in four equal installments beginning on December 10, 2022. Read SEC document |
| December 10, 2024 Filed Dec 11, 2024 21:51 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-24-000196 · wk-form4_1733953906.xml · derivative · entry 8 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On December 10, 2020, the Reporting Person was granted 8,000 RSUs which vest in four equal installments beginning on December 10, 2021. F3 · derivative.expiration_date: On December 10, 2020, the Reporting Person was granted 8,000 RSUs which vest in four equal installments beginning on December 10, 2021. Read SEC document |
| December 10, 2024 Filed Dec 11, 2024 21:51 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Tax withholdingCommon Stock | 2,773 | $29.63 | $82,163.99 |
DisclosureSEC source: 0001447362-24-000196 · wk-form4_1733953906.xml · nonDerivative · entry 6 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,365 Read SEC document |
| December 10, 2024 Filed Dec 11, 2024 21:51 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 6,169 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001447362-24-000196 · wk-form4_1733953906.xml · nonDerivative · entry 5 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| December 10, 2024 Filed Dec 11, 2024 21:51 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Tax withholdingCommon Stock | 900 | $29.63 | $26,667.00 |
DisclosureSEC source: 0001447362-24-000196 · wk-form4_1733953906.xml · nonDerivative · entry 4 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,969 Read SEC document |
| December 10, 2024 Filed Dec 11, 2024 21:51 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 2,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001447362-24-000196 · wk-form4_1733953906.xml · nonDerivative · entry 3 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| December 09, 2024 Filed Dec 11, 2024 21:51 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 14,617 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-24-000196 · wk-form4_1733953906.xml · derivative · entry 7 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,233 Underlying: Common Stock · 14,617 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: On December 9, 2022, the Reporting Person was granted 58,467 RSUs which vest in four equal installments beginning on December 9, 2023. F2 · derivative.expiration_date: On December 9, 2022, the Reporting Person was granted 58,467 RSUs which vest in four equal installments beginning on December 9, 2023. Read SEC document |
| December 09, 2024 Filed Dec 11, 2024 21:51 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Tax withholdingCommon Stock | 6,571 | $30.91 | $203,109.61 |
DisclosureSEC source: 0001447362-24-000196 · wk-form4_1733953906.xml · nonDerivative · entry 2 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,869 Read SEC document |
| December 09, 2024 Filed Dec 11, 2024 21:51 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 14,617 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001447362-24-000196 · wk-form4_1733953906.xml · nonDerivative · entry 1 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 21:04 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 800 | $30.40 | $24,323.20 |
DisclosureSEC source: 0001447362-24-000187 · wk-form4_1732050241.xml · nonDerivative · entry 2 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,823 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 13, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $30.400 to $30.425, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 21:04 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 6,123 | $29.87 | $182,894.01 |
DisclosureSEC source: 0001447362-24-000187 · wk-form4_1732050241.xml · nonDerivative · entry 1 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,623 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 13, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $29.40 to $30.35, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 22:14 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantPerformance-Based Stock Unit · Derivative | 9,744 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-24-000130 · wk-form4_1723587271.xml · derivative · entry 3 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,744 Underlying: Common Stock · 9,744 shares Expires not disclosed F2 · derivative.exercise_price: Each PSU represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the 2022 PSUs which are all subject to time-based vesting and will vest in full on the one-year anniversary of the Initial Vesting Date. F2 · derivative.exercise_date: Each PSU represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the 2022 PSUs which are all subject to time-based vesting and will vest in full on the one-year anniversary of the Initial Vesting Date. F2 · derivative.expiration_date: Each PSU represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the 2022 PSUs which are all subject to time-based vesting and will vest in full on the one-year anniversary of the Initial Vesting Date. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 22:14 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Tax withholdingCommon Stock | 2,822 | $26.83 | $75,714.26 |
DisclosureSEC source: 0001447362-24-000130 · wk-form4_1723587271.xml · nonDerivative · entry 2 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,746 Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 22:14 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantCommon Stock | 9,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-24-000130 · wk-form4_1723587271.xml · nonDerivative · entry 1 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,568 F1 · shares: Represents 50% of the Performance-Based Stock Units ("PSUs") granted on December 23, 2022 ("2022 PSUs") that vested based on the satisfaction of certain performance criteria as certified by the board of directors of the Issuer on August 9, 2024 (the "Initial Vesting Date"). Read SEC document |
| August 07, 2024 Filed Aug 13, 2024 22:13 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 5,400 | $26.13 | $141,091.20 |
DisclosureSEC source: 0001447362-24-000129 · wk-form4_1723587221.xml · nonDerivative · entry 2 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,823 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Frank Stokes on May 06, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $25.845 to $26.405, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 07, 2024 Filed Aug 13, 2024 22:13 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,600 | $25.20 | $115,906.20 |
DisclosureSEC source: 0001447362-24-000129 · wk-form4_1723587221.xml · nonDerivative · entry 1 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,223 F1 · kind: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Frank Stokes on May 06, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.840 to $25.535, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: Includes 1,272 shares acquired on February 29, 2024, under the Issuer's employee stock purchase plan. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 20:07 UTC | EXAGEN INC. XGN · Entity 935 | GrantStock Option(right to buy) · Derivative | 9,000 | $0.00 Strike: $1.99 | $0.00 |
DisclosureSEC source: 0001274737-24-000064 · wk-form4_1718222835.xml · derivative · entry 1 Stokes Frank · CIK 0001782815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2034-06-09 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 23:00 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantRestricted Stock Units · Derivative | 48,744 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-24-000023 · wk-form4_1709766033.xml · derivative · entry 1 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,744 Underlying: Common Stock · 48,744 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSU's vest in four equal annual installments beginning on March 04, 2025. F2 · derivative.expiration_date: The RSU's vest in four equal annual installments beginning on March 04, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.